Photo by andrea_natali from unsplash
demonstrate that the pembrolizumab Q6W scheme could generate a cost savings of V 1.2, V 2.2 and 3.0 million for 1,000 patients if compared with pembrolizumab Q3W, nivolumab and ipilimumab… Click to show full abstract
demonstrate that the pembrolizumab Q6W scheme could generate a cost savings of V 1.2, V 2.2 and 3.0 million for 1,000 patients if compared with pembrolizumab Q3W, nivolumab and ipilimumab respectively. On average, 40% of these cost reductions were associated with adjuvant treatment patients. Conclusions: The ability to reduce the admissions for drug administration in hospital due to a new therapeutic scheme of pembrolizumab, could generate and efficient management of the oncological ambulatory reducing the number of patients that have to come in hospital.
Journal Title: Value in Health
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!